Twist Bioscience Corporation (NASDAQ: TWST) reported Q3 EPS of ($1.01), $0.11 better than the analyst estimate of ($1.12). Revenue for the quarter came in at $63.7 million versus the consensus estimate of $60.56 million.

Fiscal 2024 Financial Guidance:

For the full fiscal year 2024, Twist provided the following financial guidance:

Twist expects to exit fiscal 2024 with adjusted EBITDA breakeven for its core (SynBio, NGS) business in the fourth quarter
Operating expenses for DNA data storage are expected to be $40 million
Fiscal year end cash is projected to be $220 million

For earnings history and earnings-related data on Twist Bioscience Corporation (TWST) click here.